Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03372941
Other study ID # 201709136
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date March 4, 2019
Est. completion date October 14, 2021

Study information

Verified date November 2022
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources.


Description:

This study seeks to establish the feasibility and acceptability of an alternative treatment strategy for uncomplicated acute bacterial skin and skin structure infection (ABSSSI) in the Barnes Jewish Hospital (BJH) Emergency Department (ED) focusing on hospital admission avoidance using single-dose, long-acting antimicrobial therapy complemented by close follow-up in the ambulatory setting. The extended half-life of these new antimicrobials (dalbavancin, oritavancin) allows for an effective treatment course of >7 days with a single dose, which is the accepted duration for which ABSSSI is usually treated with daily doses of other intravenous or oral antimicrobials. The investigators believe that such an approach will conserve hospital resources by reducing admissions for uncomplicated ABSSSI while delivering comparable if not superior care for this disease, allowing optimal utilization of BJH inpatient beds for other serious medical conditions requiring inpatient care. The investigators believe this novel alternative approach will allow hospitals such as BJH to more cost-effectively and efficiently manage ABSSSI patients. This study will reduce the number of >2 midnight observation admissions to BJH for ABSSSI, thereby improving inpatient capacity to care for patients requiring >2 midnight hospital inpatient admission. The investigators will conduct a randomized controlled trial comparing patients treated with a single-dose of intravenous dalbavancin (an antibiotic that has been FDA-approved for the treatment of ABSSSI and is currently being used in clinical practice in the U.S.) and discharged home from the ED with close ambulatory care follow-up in clinic vs. patients treated with "usual care" (hospital admission for multiple doses of intravenous vancomycin or other antibiotic directed towards Gram-positive bacteria). Clinical outcomes, healthcare utilization, hospital costs, and patient satisfaction will be evaluated.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date October 14, 2021
Est. primary completion date October 14, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult (age =18 years) - Diagnosis of uncomplicated ABSSSI suspected to be due to Gram-positive bacteria by treating ED clinician, with presence of the following: 1. Skin lesion size =75 cm2 (measured by area of erythema, edema, and/or induration) AND 2. Signs of systemic inflammation (at least 1 of the following: WBC >12,000 or <4,000 cells/mm3; =10% immature neutrophils on peripheral smear; temperature >38.3°C or <36°C; heart rate >90 bpm, respiratory rate >20 bpm). Signs of systemic inflammation not required if the patient is age >70 years, has diabetes mellitus, or has been treated with immunosuppressive or chemotherapy in the past 90 days. - Clinical determination by treating ED clinician that patient will need hospital admission for the sole purpose of receiving intravenous antibiotics directed only towards Gram-positive bacteria (e.g., vancomycin, cefazolin) to treat uncomplicated ABSSSI Exclusion Criteria: - Risk for ABSSSI due to Gram-negative bacteria (neutropenia with absolute neutrophil count <500 cells/µL, HIV or severely immunocompromised, burns, infection after trauma or as a result of an aquatic environment, infection after skin graft) - Any abscess requiring bedside or operative drainage - Infection due to a vascular catheter or prosthetic device - Infection of a diabetic foot ulcer or decubitus ulcer - Necrotizing soft tissue infection - Sepsis (quick SOFA score =2) or septic shock (requiring vasopressors to maintain mean arterial pressure =65 mmHg despite resuscitation with at least 30mL/kg of IV crystalloid within first 3 hours) - Recent antibiotics in prior 14 days - Hypersensitivity to glycopeptides (vancomycin, televancin, dalbavancin, oritavancin) - Severe renal insufficiency (CrCl <30 mL/min) - Severe hepatic insufficiency (Child-Pugh Class C) - Pregnant or nursing

Study Design


Intervention

Drug:
Dalbavancin
Dalbavancin, a lipoglycopeptide antibiotic, has been approved by the FDA for the treatment of ABSSSI caused by Gram-positive bacteria. A single dose of dalbavancin will be administered in the Emergency Department followed by discharge with close outpatient infectious disease clinic follow-up.

Locations

Country Name City State
United States Barnes-Jewish Hospital Saint Louis Missouri

Sponsors (3)

Lead Sponsor Collaborator
Washington University School of Medicine Allergan, The Foundation for Barnes-Jewish Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Healthcare Utilization Related to ABSSSI Repeat ED visit(s) within 28 days, need for hospital admission(s) to receive intravenous antibiotics ("alternative treatment strategy" arm), or need for switch to different oral or intravenous antibiotic to treat ABSSSI ("usual care" arm) 28 days
Secondary Healthcare Cost Related to ABSSSI Management Indirect/direct costs associated with ED visit(s), indirect/direct costs associated with hospital admission(s) 28 days
Secondary Clinical Response Change in ABSSSI lesion area (cm2) 28 days
Secondary Clinical Success Clinical resolution of symptoms, need for additional intravenous/oral antibiotic therapy 28 days
Secondary Overall Patient Satisfaction Based on Standardized Measures Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey items 28 days
Secondary Patient Satisfaction Specific to ABSSSI Care Targeted survey questions specific to ABSSSI and patient-centered outcomes with relation to alternative treatment strategy vs. usual care 28 days
Secondary Patient Safety Adverse drug events 28 days
Secondary Quality of Life Measured Using RAND SF-36 Survey RAND SF-36 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed NCT03929224 - The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown Phase 4
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT03637400 - Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment Phase 2
Completed NCT06149117 - Bioequivalence Study of Azithromycin Capsule and Reference Formulation Sumamed * in Healthy Adult Subjects in China Phase 4
Active, not recruiting NCT05226260 - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care N/A
Recruiting NCT03131843 - Effectiveness of Alcohol Swabs for Preventing Infections During Vaccination Phase 3
Recruiting NCT04278404 - Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Completed NCT02512614 - Evaluation of Novel Antimicrobial Hand Towels Phase 2/Phase 3
Completed NCT01593761 - Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus Phase 2
Not yet recruiting NCT06247761 - STASSH - TRAUMA - Absorbable vs Non-Absorbable Sutures in Trauma Hand Surgery N/A
Not yet recruiting NCT06170983 - Skin Inflammation and PK of Azithromycin N/A
Completed NCT02052388 - Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections Phase 2
Completed NCT00619710 - Complicated Skin and Skin Structure Infections Phase 3
Recruiting NCT05339802 - A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections Phase 2
Completed NCT06087809 - Improving Short Course Treatment for Common Pediatric Infections N/A
Not yet recruiting NCT05899140 - Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial Phase 4